ERA4TB project is a public-private initiative devoted to accelerating the development of new treatment regimens for tuberculosis. It is expected to revolutionize how tuberculosis treatments are developed thanks to its parallelized, multi-entry pipeline structure, analogue to a production line. This structure will enable to systematically investigate the efficacy of several drug candidates and combinations simultaneously while allowing new molecules to enter the project pipeline at the research stage corresponding to the degree of knowledge on said candidate drugs gathered before the project.

With this approach, the ERA4TB consortium expects to reduce the time required for the development of new tuberculosis treatment regimens by up to a quarter.


The ERA4TB initiative integrates more than thirty organizations from the European Union and the United States among which are the main global actors in the fight against tuberculosis infection.

ERA4TB has started in 2020 and will last six years, at the end of which, the consortium expects to have developed at least two or more new combination regimens with treatment-shortening potential ready for Phase II clinical evaluation. The partners intend to maintain the ERA4TB platform active beyond the project official duration.

Follow us on Twitter: @IMI_ERA4TB
Sign up to our newsletter: https://era4tb.org/newsletter-july-2021/

ERA4TB

Org chart

Teams

Offices